DIA Presentations, Philadelphia, PA, June 2006

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research

Key: PDF = Adobe Acrobat file; PPT = Microsoft Powerpoint file

Program, 42nd Annual Meeting of the Drug Information Association, June 18-22, 2006, Philadelphia, PA [PDF]

Presentations ordered by Author's last name:

Alexander, John, Medical Team Leader, FDA Division of Anti-infective and Ophthalmology Products; Best Pharmaceuticals for Children Act BPCA: Pediatric Safety Review and the Medical Officer [PPT] [PDF]
Behrman, Rachel, MD, MPH, FDA Office of Medical Policy; The New Content and Format Requirements for Prescription Drug Labeling - Leaner, Cleaner, More Precise [PPT] [PDF]
Bass, Steven, PhD, Bristol-Myers Squibb, Burke, Laurie, RPh, MPH, FDA, Fava, Jamie, PharmD, Bristol-Myers Squibb; Prescription Drug Labeling: Implementation of FDA’s New Regulation for the Content and Format of the USPI and Accompanying Documents [PPT] [PDF]
Burke, Laurie, RPh, MPH, FDA, Rock, Edwin, MD, PhD, FDA, Powers, John, FACP, MD, FDA, Robert O’Neill, PhD, FDA; Patient-reported Outcome Instruments: Overview and Comments on the FDA Draft Guidance [PPT] [PDF]
Chen, Yeh-Fong, FDA Division of Biometrics; How Long Should Antidepressant Drugs be Continued to Prevent Relapse in Clinical trials? [PPT] [PDF]
Clark, Jon, MS, Associate Director, FDA Office of Pharmaceutical Science Policy Development; Briefing on Development of QMS for CDER and CBER [PPT] [PDF]
Collier, Bronwyn, BSN, Associate Director for Regulatory Affairs, FDA Center for Drug Evaluation and Research; eCTD: Module 1: From submission to reviewer [PPT] [PDF]
Cooper, Charles, Clinical Reviewer, FDA Office of Biostatistics; Use of New Tools for Safety Analysis [PPT] [PDF]
Cummins, Susan, MD, MPH, Executive Director, FDA Drug Safety Oversight Board; Drug Safety Oversight Board Update [PPT] [PDF]
Cummins, Susan, MD, MPH, Executive Director, FDA Drug Safety Oversight Board; Regulatory Affairs, DSB update; CDER Hot Topic-Update: Drug Safety Initiatives [PPT] [PDF]
Dal Pan, Gerald, MD, MHS, Director, FDA Office of Surveillance and Epidemiology; Office of Drug Safety Update [PPT] [PDF]
Dal Pan, Gerald, MD, MHS, Director, FDA Office of Surveillance and Epidemiology; Active Surveillance as a Post-marketing Drug Safety Tool [PPT] [PDF]
El-Hage, Jeri, PhD, Co-chair of Pharmacokinetics/Toxicokinetics Committee, Supervisory Pharmacologist, Division of Metabolism and Endocrinology Products; Safety Testing of Drug Metabolites [PPT] [PDF]
El-Hage, Jeri, PhD, Supervisory Pharmacologist, Division of Metabolism and Endocrinology Products; Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Preclinical and Clinical Cardiac Safety Considerations [PPT] [PDF]
Famulare, Joseph, Acting Deputy Director, FDA Office of Compliance; FDA CDER Compliance Initiatives [PPT] [PDF]
Gensinger, Gary, MBA, Director, Regulatory Review Support Staff, Office of Business Process Support; Standards and Successful Document Creation [PPT] [PDF]
Goodman, Vicki, MD, FDA Office of Oncology Drug Products; FDA Perspective on Innovative Trial Designs in Oncology [PPT] [PDF]
Goodsaid, Federico, PhD, FDA Office of Clinical Pharmacology; FDA-EMEA Joint Session on Emerging Therapies and Technologies [PPT] [PDF]
Goodsaid, Federico, PhD, FDA Office of Clinical Pharmacology; Joint USFDA-EU Pharmacogenomic Initiatives [PPT] [PDF]
Green, Lanh, Pharm D, MPH, FDA Office of Surveillance and Epidemiology; Postmarketing Pharmacovigilance Practice at FDA [PPT] [PDF]
Jansen, Deborah, Center Lab Quality Manager, FDA Center for Biologics Evaluation and Research; What Do You Mean When You Say Quality System? [PPT] [PDF]
Justice, Robert, MD, MS, FDA Division of Drug Oncology Products; How FDA Will Work with Sponsors to Accelerate Oncology Drug Development in the Era of Critical Path [PPT] [PDF]
Karwoski, Claudia, Pharm D, Scientific Coordinator for Risk Management, FDA Office of Surveillance and Epidemiology; Practical Experience with Risk Management Plans in the US [PPT] [PDF]
LoCicero, Colleen, RPh, Associate Director for Regulatory Affairs, FDA Office of Drug Evaluation I; Labeling for Human Prescription Drug and Biological Products – Implementing the New Content and Format Requirements (“Implementation Guidance”) [PPT] [PDF]
Molzon, Justina, MS, Pharm, JD, Associate Director for International Programs, FDA Center for Drug Evaluation and Research; ISS/ISE: Where Do They Fit in the CTD/eCTD? [PPT] [PDF]
Murray, Jeff, MD, MPH, Deputy Director, Division of Antiviral Products; Clinical Perspective of Endpoint Selection for HIV Clinical Trials in Treatment-Experienced Populations [PPT] [PDF]
Oliva, Armando, MD, Associate Director for Policy, FDA Office of New Drugs; ISE/ISS Analyses: Clarity in a CTD or eCTD – Clinical Reviewer Perspective [PPT] [PDF]
Pauls, Lana, MPH, Director, FDA Quality Management Staff; QMS: The Impact on Drug Safety Process Improvement [PPT] [PDF]
Pauls, Lana, MPH, Director, FDA Quality Management Staff; The Quality System (QS) Train is Moving Fast at FDA [PPT] [PDF]
Phelan, Kathleen, R Ph, Safety Evaluator, FDA Office of Surveillance and Epidemiology; Pediatric Postmarketing Safety Reviews: Methods and Findings [PPT] [PDF]
Rock, Edwin, MD, PhD, FDA Office of Oncology Drug Products; Regulatory Considerations [PPT] [PDF]
Seligman, Paul, MD, MPH, Associate Director for Safety Policy and Communication, FDA Center for Drug Evaluation and Research; CDER Hot Topics Drug Safety Update [PPT] [PDF]
Shapiro, Alan, MD, PhD, Medical Officer, FDA Division of Pediatric Drug Development; Implementation of the Best Pharmaceuticals for Children Act: the FDA Pediatric Post-Marketing Safety Review Experience [PPT] [PDF]
Stockbridge, Norman, FDA Office of New Drugs; A Modest Proposal for a Simple Trial Designer [PPT] [PDF]
Temple, Robert, MD, Associate Director for Medical Policy, FDA Center for Drug Evaluation and Research; CTD – ISS/ISE Introduction and Summary of Issues [PPT] [PDF]
Unger, Ellis, MD, FDA Office of New Drugs; Background and Overview of the CIOMS VII Project: The DSUR [PPT] [PDF]
Vaccari, Leslie, BSN, RAC, Project Management Officer, FDA Botanical Review Team; Current Regulation of Botanical Drugs in the United States [PDF]
Ventura, Virginia, Regulatory Information Specialist, FDA Office of Business Process Support; Guidance Compliant eCTDs Module 2: Summaries [PPT] [PDF]
Ventura, Virginia, Regulatory Information Specialist, FDA Office of Business Process Support; eSUBS and eCTDs: Practical Advice and Pitfalls to Avoid [PPT] [PDF]
Yu, Lawrence, PhD, Director for Science, FDA Office of Generic Drugs; Implementation of Quality-by-Design: Question-based Review [PPT] [PDF]
Zhou, Feng, Statistician, FDA; Stephan Wilson, Division Director, FDA; A Statistical Reviewer's Perspective [PPT] [PDF]

PDF requires the free Adobe Acrobat Reader

Date created: July 10, 2006